🔑 Key Takeaways
- CagriSema (semaglutide + cagrilintide) achieved 22.7% mean weight loss in Phase 3 — the strongest clinical data to date
- Amycretin is a single-molecule dual agonist hitting both GLP-1 and amylin receptors from one peptide chain, with up to 25% weight loss in early trials
- Both are from Novo Nordisk — they're running parallel strategies to dominate the next generation of obesity treatment
- CagriSema has more clinical evidence (Phase 3 complete); amycretin has potentially better oral formulation prospects
- Neither is FDA-approved or commercially available as of mid-2026
Novo Nordisk is essentially competing against itself. They have two distinct approaches to the same problem — combining GLP-1 and amylin receptor activation for maximum weight loss — and both are producing numbers that make current treatments look modest by comparison. CagriSema takes two proven molecules and puts them in one syringe. Amycretin engineers a single peptide that does both jobs simultaneously.
The result? A genuine scientific horse race between co-administration and unimolecular design. And the implications for obesity pharmacotherapy are enormous either way. Let's break down what each approach actually is, what the clinical data shows, and which one is likely to matter more.
The Core Difference: One Molecule vs. Two
This is the fundamental distinction and it shapes everything else about these therapies.
Amycretin: Dual Agonism from a Single Peptide
Amycretin is a synthetic peptide engineered to simultaneously activate both GLP-1 receptors and amylin receptors (AMY1, AMY2, AMY3) from a single molecular chain. This is an extraordinary piece of medicinal chemistry — creating one peptide that mimics the binding properties of two naturally different hormones.
GLP-1 receptor agonism provides appetite suppression, slowed gastric emptying, and glucose-dependent insulin potentiation. Amylin receptor agonism provides complementary satiety signaling through distinct CNS pathways — particularly hypothalamic and brainstem circuits. The combination targets food intake from two different angles simultaneously.
The key advantages of the unimolecular approach: simpler pharmacokinetics (one absorption curve, one clearance pathway), potentially simpler manufacturing at scale, and the possibility of oral formulation — which Novo Nordisk is actively pursuing.
CagriSema: Fixed-Ratio Co-Administration
CagriSema pairs semaglutide 2.4mg with cagrilintide 2.4mg in a single weekly injection. The compounds are co-formulated but remain two distinct molecules with independent pharmacokinetic profiles. Semaglutide is the same GLP-1 agonist in Wegovy (FDA-approved, billions in sales, massive evidence base). Cagrilintide is a long-acting amylin analogue with its own Phase 2 and Phase 3 data.
The advantage here is that each component has been independently validated. Semaglutide's safety and efficacy profile is among the most extensively characterized in pharmaceutical history. Cagrilintide brings complementary amylin biology without duplicating semaglutide's mechanism. Together, they produce genuinely synergistic weight loss — not just additive.
Clinical Data: Head-to-Head Comparison
| Metric | Amycretin | CagriSema |
|---|---|---|
| Developer | Novo Nordisk | Novo Nordisk |
| Mechanism | Unimolecular GLP-1/amylin dual agonist | Semaglutide + cagrilintide co-administration |
| Phase | Phase 1b/2 (Phase 3 initiating 2026) | Phase 3 (REDEFINE program complete) |
| Max weight loss reported | ~25% (early trial, 36 weeks SC) | 22.7% (REDEFINE 1, 68 weeks) |
| Oral formulation | In development (~13% at 36 weeks oral) | Not planned |
| Dosing frequency | Once weekly (SC) or once daily (oral) | Once weekly (SC only) |
| FDA approval | Not yet | Not yet (expected ~2026–2027) |
| GI tolerability | Similar to GLP-1 class | Generally well-tolerated; milder than some reports |
Amycretin Trial Data
The subcutaneous amycretin data made headlines: approximately 25% body weight reduction at 36 weeks in early-phase trials. That number, if it holds in larger studies, would represent the most effective injectable anti-obesity pharmacotherapy ever reported. The oral formulation data is equally noteworthy — approximately 13% weight loss at 36 weeks from a daily pill, which approaches what current injectable semaglutide achieves.
The caveats are important. These are early-phase results with smaller sample sizes. Phase 1b/2 trials are designed primarily to establish safety and dose-ranging, not to provide definitive efficacy estimates. The confidence intervals around these numbers are wider than Phase 3 data. And the 25% figure represents the highest-responding dose arm — not necessarily the dose that will be selected for Phase 3 based on the tolerability-efficacy balance.
CagriSema Trial Data
CagriSema's evidence base is substantially more mature. The REDEFINE program includes multiple Phase 3 trials across different populations:
- REDEFINE 1: 22.7% mean weight loss at 68 weeks in adults with obesity (no diabetes). Published in NEJM.
- REDEFINE 2: Data in Type 2 diabetes populations
- Superresponders: ~40% of participants in REDEFINE 1 lost ≥25% body weight
- Completion rates: Generally favorable, suggesting acceptable tolerability
The 22.7% mean figure is extraordinary on its own — higher than semaglutide 2.4mg alone (~15% in STEP trials) and higher than tirzepatide alone (~21% in SURMOUNT-1). But perhaps more telling is the distribution: the proportion of patients reaching clinically meaningful thresholds (15%, 20%, 25%) was substantially higher than any currently approved therapy.
Why Novo Nordisk Is Running Both Programs
This isn't unusual in pharma — running parallel development programs is a hedge against failure and a way to capture different market segments. Here's the strategic logic:
CagriSema: The Near-Term Play
CagriSema uses two molecules that Novo Nordisk already manufactures at scale (semaglutide is their flagship product). Phase 3 is complete. Regulatory submission is imminent. It's the compound most likely to reach the market first and become the standard-of-care upgrade from semaglutide monotherapy.
Amycretin: The Long-Term Play
Amycretin's oral potential is its strategic killer feature. If Novo Nordisk can deliver 20%+ weight loss from a daily pill — not an injection — that's a fundamentally larger addressable market. Oral semaglutide (Rybelsus) already demonstrated that oral GLP-1 is commercially viable despite lower efficacy than injectable. An oral dual agonist with injectable-level efficacy would be transformative.
Mechanism Deep Dive: Why Dual Pathways Work
The reason GLP-1 + amylin produces synergistic (not just additive) weight loss comes down to pathway complementarity.
GLP-1 Pathway
GLP-1 receptor agonism acts primarily through peripheral mechanisms: slowed gastric emptying (you feel full longer after eating), reduced glucagon secretion (better blood sugar), and direct hypothalamic effects on appetite. The satiety signal is strong but has a ceiling — you can only slow gastric emptying so much before GI side effects become limiting.
Amylin Pathway
Amylin receptor agonism works through distinct CNS circuits. It activates neurons in the area postrema and nucleus of the solitary tract — brainstem regions that process satiety differently from the hypothalamic circuits GLP-1 targets. Amylin also affects food reward pathways, potentially reducing hedonic eating (eating for pleasure rather than hunger). This is a different "flavor" of appetite suppression.
The Synergy
When you hit both pathways simultaneously, you create a more complete satiety signal than either pathway alone. It's like turning down the volume on two different channels of hunger simultaneously — peripheral fullness signals AND central reward/satiety signals. The result: patients eat less without the extreme GI distress that would come from maximizing a single pathway.
This synergy is why CagriSema at semaglutide 2.4mg + cagrilintide 2.4mg outperforms semaglutide 2.4mg alone by such a wide margin — it's not just "more drug," it's a qualitatively different satiety signal.
Safety and Side Effects Comparison
Common Side Effects (Both Therapies)
Both amycretin and CagriSema share the GI side effect profile typical of GLP-1-based therapies:
- Nausea (most common; dose-dependent, typically peaks during escalation)
- Vomiting (less common; usually transient)
- Diarrhea or constipation
- Decreased appetite (intended effect, listed as "side effect" by convention)
- Injection site reactions (for subcutaneous formulations)
CagriSema-Specific Observations
The REDEFINE data suggests CagriSema may have a somewhat milder GI side effect profile than expected for this level of efficacy. The hypothesis: because the amylin component provides satiety through a different pathway, the GLP-1 component doesn't need to be pushed to doses that maximize GI effects. Two moderate signals instead of one extreme signal.
Amycretin-Specific Observations
Early-phase data shows GI tolerability comparable to existing GLP-1 agonists. The oral formulation introduces the additional consideration of daily dosing vs. weekly — daily pills mean daily GI exposure but potentially smoother pharmacokinetics without weekly peak-trough dynamics.
How They Compare to Current Treatments
| Therapy | Mechanism | Mean Weight Loss | Administration | Status |
|---|---|---|---|---|
| Semaglutide 2.4mg (Wegovy) | GLP-1 agonist | ~15% | Weekly SC injection | FDA approved |
| Tirzepatide (Zepbound) | GLP-1 + GIP dual agonist | ~21% | Weekly SC injection | FDA approved |
| Retatrutide | GLP-1 + GIP + Glucagon triple agonist | ~24% | Weekly SC injection | Phase 3 |
| CagriSema | GLP-1 + Amylin (two molecules) | 22.7% | Weekly SC injection | Phase 3 complete |
| Amycretin (SC) | GLP-1 + Amylin (one molecule) | ~25% | Weekly SC injection | Phase 1b/2 |
| Amycretin (oral) | GLP-1 + Amylin (one molecule) | ~13% | Daily oral pill | Phase 1b/2 |
The trend is unmistakable: multi-pathway approaches consistently outperform single-pathway therapies. The question is no longer whether combination mechanisms work better — it's which combination and which delivery format wins the market. For researchers following the broader landscape, our Ozempic alternatives guide covers the full competitive picture.
Which Will Win the Market?
Honestly? Probably both, in different segments.
CagriSema's Market Position
First to market (likely). Uses proven manufacturing infrastructure. Clear upgrade path for the massive existing semaglutide patient population. Insurance coverage easier to establish with Phase 3 data. Likely becomes the standard-of-care injectable for severe obesity within 1–2 years of approval.
Amycretin's Market Position
The oral formulation is the differentiator. If it delivers 15–20%+ weight loss from a pill, it captures the enormous population who refuse injections. Even the subcutaneous version, if Phase 3 confirms the ~25% number, could compete with or surpass CagriSema on pure efficacy. Longer timeline to market but potentially larger ultimate market.
The Retatrutide Factor
Neither therapy exists in isolation. Retatrutide (from Eli Lilly) is a triple agonist (GLP-1 + GIP + glucagon) with Phase 2 data showing ~24% weight loss. If retatrutide's Phase 3 data is strong, it becomes another serious competitor — different mechanism, different company, different market dynamics.
Research Peptide Access: What's Available Now
For researchers who can't wait for FDA approval, the research peptide market offers access to some of the individual components:
- Semaglutide: Available as a research peptide from vendors like Ascension Peptides
- Cagrilintide: Available from select research peptide suppliers
- Amycretin: Not currently available as a research compound (proprietary Novo Nordisk molecule)
- Retatrutide: Available as a research peptide — see our retatrutide sourcing guide
Researchers modeling the CagriSema combination can source both components independently, though ensuring matched pharmacokinetics between separately sourced compounds requires careful protocol design.
What This Means for the Future of Obesity Treatment
The bigger picture: we're witnessing a shift from single-target pharmacotherapy to multi-pathway metabolic interventions. The era of "one drug, one receptor, moderate results" is ending. The next generation — whether it's CagriSema, amycretin, retatrutide, or something not yet in trials — will deliver 20–30% weight loss as the baseline expectation.
For patients, this means pharmacological weight loss approaching what was previously only achievable through bariatric surgery. For the healthcare system, it means potentially transformative impacts on obesity-related conditions: Type 2 diabetes, cardiovascular disease, sleep apnea, joint disease. For the pharmaceutical industry, it means a market measured in tens of billions of dollars.
